DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ABILIFY MYCITE KIT
» See Plans and Pricing
All Clinical Trials for ABILIFY MYCITE KIT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03643159 | A Trial to Measure the Difference in All-cause Hospitalizations for Patients Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 4 | 2018-06-29 | A pragmatic clinical trial (Main Study) to assess the difference between all-cause hospitalizations in patients using Abilify MyCite versus virtual matched controls. Eligible patients will enter a screening period of up to 13 days. At enrollment, patients will receive treatment with Abilify MyCite for 3 months and discontinue the use of Abilify MyCite during the following 3 months (and the patient continues with oral aripiprazole or other appropriate treatment). Thereafter, the patient has the option to start and stop Abilify MyCite (up to 6 months of Abilify MyCite) per the joint decision of the patients with their study physician. A parallel exploratory study will utilize a different set of physicians and patients from the main study. Procedures for the exploratory study will be similar to those in the Main Study, with the exception that there will be 1-month intervals of Abilify MyCite use (and 1-month intervals of prohibition of Abilify MyCite use). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ABILIFY MYCITE KIT
Condition Name
Clinical Trial Locations for ABILIFY MYCITE KIT
Trials by Country
Clinical Trial Progress for ABILIFY MYCITE KIT
Clinical Trial Phase
Clinical Trial Sponsors for ABILIFY MYCITE KIT
Sponsor Name
